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Colon carcinoma is one of the most frequent malignancies and one
of the main causes of cancer deaths in industrialised countries. In
Switzerland, it is estimated that each year approximately 1100
men and 1050 women are diagnosed with colon carcinoma (Levi
et al, 1998). Despite the rather favourable prognosis, only half of
the patients survive 5 years after diagnosis (Gatta et al, 1996;
Berrino et al, 1999). 
The only curative option for patients with colon carcinoma is
surgery (Cohen et al, 1997). For stage I disease (Dukes’ stage A
and B-1 (Astler and Coller, 1954) invasion to the muscularis
propria without nodal involvement) there is more than 90% proba-
bility of cure. This probability drops to approximately 75% for the
stage II disease (Dukes’ stage B-2, invasion into or through the
serosa, without nodal involvement), and reaches only approxi-
mately 35% for the stage III disease (Dukes’ stage C, metastasis to
regional lymph nodes). The poor prognosis of nonmetastatic
advanced disease is due to residual cancer in occult or microscopic
form, for which chemotherapy or immunotherapy is most effective
(Cohen et al, 1997). 
At the end of the 1980s, randomised clinical trials provided
evidence that adjuvant postoperative chemotherapy in colon carci-
noma patients with regional lymph node metastasis increases the
survival rates by approximately 30% (Laurie et al, 1989; Moertel
et al, 1990; IMPACT, 1995). Data were less convincing for
patients without positive lymph nodes. 
Based on these evidences and given the infrequent toxic side
effects, therapeutic guidelines were established in 1990, recom-
mending systematic adjuvant chemotherapy after surgery for
stage III colon carcinoma (NIH consensus conference, 1990).
Recommendations are not always followed, and therefore great
disparities may exist between guidelines and practice. There are
nearly no data on the generalisation of such practice among the
population and on the observed benefits outside clinical trials. This
study evaluates the use and benefit of such therapy in routine
health care practice in the Swiss canton of Geneva. 
MATERIALS AND METHODS 
The data were derived from the Geneva cancer registry data set,
which includes information on all incident cases of malignant
neoplasms occurring in the population of the canton, approxi-
mately 400 000 inhabitants. The registration collects information
from various sources and is considered accurate. This can be
attested in particular by the very low percentage (< 2%) of cases
recorded from death certificates only (Bouchardy, 1997).
Notification is based on a voluntary agreement between the
recording medical institutions of the canton and the registry. All
hospitals, pathological laboratories and practitioners are requested
to report all current and past cancer cases. Data are systematically
abstracted from hospital and laboratory records by trained tumour
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secure missing clinical and therapeutic data. Death certificates are
consulted systematically. 
Recorded data include sociodemographic information (age,
gender, nationality, place of birth, marital status and occupation),
diagnostic circumstances (origin of diagnosis, presence of symp-
toms and methods of assessment), tumour characteristics (primary
site, histologic type and differentiation coded according to the
International Classification of Diseases for Oncology (ICD-O) )
(World Health Organization, 1976), stage of disease at diagnosis,
treatment during the first 6 months after diagnosis (surgery, radio-
therapy or chemotherapy), finality of treatment (curative, pallia-
tive or not specified), survival status and cause of death. 
The Geneva cancer registry previously published a description
of the survival assessment (Raymond et al, 1996). In brief, the
index date for incidence refers to the confirmation date of diag-
nosis, or to the date of hospitalisation if it precedes the diagnosis
and is related to the disease. The registry performs 2 types of
follow-up. In addition to passive follow-up (routine examination
of death certificates and hospital records), an active follow up is
carried out routinely each year using the files of the Cantonal
Population Office. For deceased patients, the cause of death is
determined from clinical records and recorded systematically
according to the World Health Organization classification (World
Health Organization, 1967). 
Patient selection 
The study was limited to colon carcinoma (ICD-O code 153).
Cancers of the rectum and rectosigmoid junction (ICD-O codes
154.0 and 154.1) were not considered. Between 1990 and 1996,
930 patients with histologically confirmed first primary invasive
colon carcinoma (excluding 4 malignant tumours other than carci-
noma) were recorded in the resident population of the Swiss
canton of Geneva. The study concerned only stage III colon cancer
patients (Dukes’ stage C, metastasis to regional lymph nodes)
treated with putative curative surgery, i.e. surgery with total
macroscopic and microscopic removal (n = 182). We excluded
patients who were not operated (n = 3), or who had palliative
surgery only (n = 4) or surgery with no specification of being cura-
tive or not (n = 9). 
Variables considered 
The size of the tumour after resection (in cm) was classified in
five categories (≤ 3, ≤ 4, ≤ 5, > 5 and unknown), and the T clas-
sification of the pathological pTNM classification (International
Union against Cancer, 1992; 1987) in 4 groups: pT1 (submu-
cosa) or pT2 (muscularis propria), pT3 (subserosa, non-
peritonealized pericolic tissues), pT4 (visceral peritoneum/other
organs structures) and pTx (unknown/unclassifiable). The level
of lymph node invasion was studied using the pN classification
in four groups: pN1 (≤ 3 pericolic), pN2 (> 3 pericolic), and pN3
(nodes on named vascular trunk). The tumour classification was
coded according to the ICD-O code for histologic grading and
differentiation: grade I (well differentiated, differentiated), grade
II (moderately differentiated, moderately well differentiated),
grade III (poorly differentiated), grade IV (undifferentiated,
anaplastic) and unknown. Anatomical sites considered were:
transverse colon (ICD-O 153.1), descending colon (ICD-O
153.2), sigmoid colon (ICD-O 153.3), caecum (ICD-O 153.4),
ascending colon and appendix (ICD-O 153.5–6) and not speci-
fied (ICD-O 153.9). 
4 levels of social class (based on the patient’s last occupation or,
for unemployed women, that of the spouse) were considered: low
(manual employees, skilled and unskilled workers), middle (non-
manual employees and administrative staff), high (professionals,
executives, administrators) and unknown. 
The health care sector in charge of the colon carcinoma surgery
was of private (initial treatment in the private sector) or public
nature (initial treatment in the public sector). 
The methods of discovery (consultation following symptoms,
screening or check-up examination, fortuitous discovery during
consultation, unknown) were regrouped in 2 categories (screening,
other). Screening procedures for colon carcinoma mainly referred
to routine faecal occult blood testing or endoscopic examination. 
Additional data on the type of chemotherapy among treated
patients and on the presence of co-morbid conditions among
untreated patients were collected from clinical files. 
Statistical analysis 
Determinants of chemotherapy use 
Data were analysed through unconditional multivariate logistic
regression, considering patients with adjuvant chemotherapy as
cases and patients with no adjuvant chemotherapy as controls
(Breslow and Day, 1980). All models were log-linear fitted using
the generalised linear interaction modelling statistical package
(Francis et al, 1993). The identified factors therefore concerned
the modifiers of chemotherapy use. Factors of interest were alter-
natively age at diagnosis, gender, period of diagnosis, nationality,
marital status, social class, method of discovery, health care sector,
anatomical site, tumour differentiation, tumour size, T stage and N
stage at diagnosis. The models contained the factor of interest and
age (continuous) for estimation of the crude effect. For estimation
of the adjusted effect, we a priori decided to adjust for all other
variables linked to chemotherapy use. The significance of each
variable of interest was assessed by comparing the goodness of fit
measure (deviance according to degree of freedom) of the model
with and without the variables of interest. Results are presented as
relative risk estimates of being treated vs. untreated. 
Estimation of the effect of adjuvant chemotherapy 
The 5-year survival was estimated by the actuarial method (inter-
vals in months and standard error according to Greenwood). The
effect of adjuvant chemotherapy on 5-year specific mortality rates
was evaluated by Cox proportional hazards model accounting only
for age (in continuous), or also for factors linked to both
chemotherapy use and prognosis, such as tumour characteristics
and stage (adjusted effect). Analyses were performed using both
observed survival (total number of deaths) and specific survival
(death from colon carcinoma only). In order to evaluate the
potential variation of the effect of chemotherapy with individual 
or tumour characteristics, an interaction term involving chemo-
therapy use and age or T and N classifications, or tumour differen-
tiation was introduced in the Cox model (Hill et al, 1990). 
RESULTS 
Among the 182 colon carcinoma patients with positive lymph nodes
who had curative surgery, 55 (30%) received adjuvant chemotherapy
(the cases) and 127 did not (the controls). 89% of the treated group
1252 C Bouchardy et al 
British Journal of Cancer (2001) 85(9), 1251–1257 © 2001 Cancer Research Campaignreceived the European standard therapy, i.e. 5-Fluorouracil plus
Leucovorin (folinic acid). 
Determinants of adjuvant chemotherapy use 
Table 1 shows the patient distribution according to sociodemo-
graphic characteristics and chemotherapy use. Chemotherapy use
strongly diminished after the age of 70: approximately 50% of
patients age ≤ 70 years received chemotherapy, compared with 
< 10% of patients age ≥ 70 years. After adjusting for confounders,
the chance of being treated was more than 15-fold lower for
patients ≥ 70 compared with those < 60 years (adjusted OR: 0.06,
95% CI: 0.02–0.18). 
For 69 of the 85 patients aged ≥ 70 years who did not receive
chemotherapy, clinical information on the existence or absence of 
co-morbid conditions was available. Of those 69 patients, 22 had 
co-morbid conditions (6 alcoholic, psychiatric or nervous system
disorders; 5 pulmonary or cardiac disorders, 3 post-surgical
complications; 8 other unfavourable general conditions such as
cachexia, diabetes mellitus). For 47 patients no relevant co-morbid
conditions were reported, and their general status was described as
good. Among them, 2 patients refused treatment. For the others,
age was mentioned to be the main reason for the clinical decision
not to treat with chemotherapy. A typical sentence in the medical
records was ‘Due to the age of the patient, no adjuvant therapy was
proposed’. 
The proportion of treated patients increased over time. In 1992,
less than 20% of the patients were treated with chemotherapy. This
proportion increased to 54% in 1996. The probability of being
treated was about 8-fold higher in 1995–1996 compared with the
period 1990–1992 (adjusted OR: 7.74, 95% CI: 2.52–23.76). 
With respect to other sociodemographic factors, widowed had
approximately a 3-fold lesser chance of being treated compared
with married individuals (adjusted OR: 0.34, 95% CI: 0.08–1.26).
The chance to be treated was also lower for foreigners than for
Swiss nationals (adjusted OR: 0.65, 95% CI: 0.22–1.97), and
approximately 2-fold higher among individuals belonging to
middle or high social class (adjusted OR: 2.42, 95% CI: 0.84–7.02
and OR: 1.84, 95% CI: 0.52–6.50, respectively). However, the
effects of these factors were not significant. No gender difference
was seen. In the current series, 6% of the stage III colon carcinoma
were diagnosed by screening (Table 2). There was a significant
link between method of discovery and chemotherapy use only in
non-adjusted analyses (Table 2). 
Approximately one third of the patients had surgery in private
institutions. The proportion of patients with adjuvant chemo-
therapy was 41% in the private sector compared with 24% in the
public sector. This reflected the differences in age (mean age of the
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Table 1 Distribution of stage III colon carcinoma patients and estimation of the effect of sociodemographic characteristics on adjuvant
chemotherapy use 
Adjuvant chemotherapy Crude effect Adjusted effect 
Yes No ORa (95%CI) ORb (95%CI) 
(cases) (controls)
n = 55 n = 127
Age group (years) 
<6 0 2 3 2 2 1 c 1c
60–69 23 20 1.10 (0.48–2.54) 0.72 (0.27–1.94) 
≥ 70 9 85 0.10*** (0.04–0.25) 0.06*** (0.02–0.18) 
Gender 
Male 29 62 1c 1c
Female 26 65 0.78 (0.38–1.61) 0.62 (0.27–1.44) 
Period of diagnosis 
1990–1992 14 61 1c 1c
1993–1994 17 40 1.78 (0.71–4.43) 2.28 (0.78–6.68) 
1995–1996 24 26 4.88*** (1.93–12.3) 7.74*** (2.52–23.76) 
Civil status 
Married 35 65 1c 1c
Widowed 4 36 0.48 (0.14–1.59) 0.34 (0.08–1.26) 
Single 8 14 0.89 (0.36–2.60) 0.68 (0.19–2.50) 
Other 8 12 1.54 (0.52–4.56) 1.69 (0.44–6.51) 
Nationality 
Swiss 44 105 1c 1c
Other 11 22 0.41 (0.15–1.14) 0.65 (0.22–1.97) 
Social class 
Low 10 43 1c 1c
Middle 32 52 2.06 (0.84–5.04) 2.42 (0.84–7.02) 
High 12 23 1.94 (0.66–5.72) 1.84 (0.52–6.50) 
Unknown 1 9 Excluded Excluded 
aOdds ratio adjusted for age (continuous); bOdds ratio adjusted for age (continuous), period (continuous), cancer sub-site (caecum,
other), differentiation (well, other), lymph node classification (N1, N2, other) and tumour classification (T1 and T2, T3, other); cReference
category; *P < 0.05, **P < 0.01, *** P < 0.001. patients privately treated was 64 years vs. 73 years for the public
sector) and the chance of being treated was similar in both private
and public practice after accounting for age (Table 2). 
Table 3 presents the patient distribution by site and stage of the
primary tumour. Caecum cancer was less frequently treated by
chemotherapy than cancers of other sites (21% vs. 32%, P = 0.20)
(Table 3). Caecum carcinoma was treated about 5 times less
compared with transverse colon carcinoma (adjusted OR: 0.23,
95% CI: 0.05–0.99) (Table 3). The proportion of treated patients
increased according to the level of tumour differentiation, with an
almost 12-fold increase in use of chemotherapy for poorly differ-
entiated tumours compared with well differentiated tumours
(adjusted OR: 12.55, 95% CI: 2.16–73.07). 
In the current series, 69% of the patients had less than 3 peri-
colic nodes invasion (N1), while 9% had a nodal invasion on
named vascular trunk (N3). The probability of being treated was
not significantly higher for N3 compared with N1 stages (adjusted
OR: 2.37, 95% CI: 0.59–9.50). However, it was significantly
lower when the tumour invaded through the muscularis propria
into subserosa, or into pericolic tissues (T3 or T4), compared with
lesser local invasion (T1 and T2), even after accounting for the
severity of nodal invasion (OR: 0.16, 95% CI: 0.03–0.86 and OR:
0.10, 95% CI: 0.02–0.42 for T4 and T3, respectively). The tumour
size had no influence on chemotherapy use. 
Effect of adjuvant chemotherapy 
After 5 years, 85 patients were still alive, 74 patients died of colon
carcinoma and 21 died of other causes. 2 patients were lost to
follow-up because they left the canton. The mean follow-up was
1138 days (standard deviation: 644). The 5-year survival of colon
carcinoma patients with positive lymph nodes and curative surgery
was 45% (standard error: 4%) for crude survival and 54% (stan-
dard error 4%) for specific survival. Since results on crude and
specific survival were very similar, we decided to present only the
observed survival data. Table 4 shows the effect of potential prog-
nostic factors on instantaneous death rates. Results were adjusted for
age, or for age plus period, T and N classifications and tumour site.
Age had no effect on prognosis when accounting for other prognostic
factors, while the effect of period and N stage remained significant. 
Regardless of age, period, site, T and N classifications, the
patients who received chemotherapy had an almost 3-fold (Hazard
ratio: 0.35, 95% CI: 0.18–0.68) significantly decreased mortality
rate. Adjustment for additional factors, such as social class and
method of discovery, did not modify the results. None of the inter-
action analyses was significant, i.e. the effect of chemotherapy
was similar regardless of age-group, stage or tumour differentia-
tion. 
As observed in Figure 1, the 5-year survival was higher in the
groups treated vs. untreated with adjuvant chemotherapy, for both
observed survival (70%, standard error: 5% vs. 34%, standard
error 3%), and specific survival (75%, standard error: 7% vs. 44%,
standard error 5%). 
Only patients who survived long enough could undergo 
chemotherapy treatment, so additional analyses were performed
on the same series, excluding 18 patients who died during the first
6 months after diagnosis. As expected, all these patients belonged
to the untreated group. 
Nevertheless, these new analyses provided similar results for
both determinants of chemotherapy use and efficacy of
chemotherapy. The hazard ratio associated with the use of
chemotherapy in multi-adjusted Cox model was 0.37 (95% CI:
0.18–0.73), i.e. very close to the results presented in Table 4. 
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Table 2 Distribution of stage III colon carcinoma patients and estimation of the effect of method of discovery, and health care sector on
adjuvant chemotherapy use 
Adjuvant chemotherapy Crude effect Adjusted effect 
Yes No ORa (95%CI) ORb (95%CI) 
(cases) (controls)
n = 55 n = 127
Method of discovery 
Other 49 117 1c 1c
Screening 6 5 4.21* (1.05–16.89) 5.23 (0.97–28.26) 
Unknown 0 5 Excluded Excluded
Health care sectord
Public 27 86 1c 1c
Private 28 41 1.05 (0.49–2.25) 1.16 (0.46–2.94) 
aOdds ratio adjusted for age (continuous); bOdds ratio adjusted for age (continuous), period (continuous), cancer sub-site (caecum, other),
differentiation (well, other), lymph node classification (N1, N2, other) and tumour classification (T1 and T2, T3, other); cReference category; 
dFirst treatment; P < 0.05, ** P < 0.01, ***P < 0.001. 
Figure 1 Survival after curative surgery for stage III colon carcinoma 
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This study shows that in daily practice the probability of receiving
adjuvant chemotherapy after surgery for stage III colon carcinoma
remains low, despite established recommendations. According to
the literature, the expected proportion of ineligible patients should
be round 5% (Moertel et al, 1990; NIH Consensus conference
1990; IMPACT, 1995), whereas we observed that still in 1996
practically 50% of the patients were not treated. 
We found very few studies providing population data on adju-
vant chemotherapy use for stage III colon carcinoma in general
practice after the publication of the therapeutic guidelines in the
1990s (NIH consensus conference, 1990). The proportion of
treated patients was 35% in a French study in 1994–1995 (Jouve
et al, 1998) and 51% in a New Jersey study in 1989–1996
(Mahoney et al, 2000). Adjuvant chemotherapy administration
strongly decreases with age. In 1996, < 13% of patients age ≥ 70
years received adjuvant chemotherapy. This could reflect the
decline of the general condition due to old age and a higher preva-
lence of co-morbid conditions, or a patient’s refusal. But also it
could be the consequence of a general unwillingness to treat the
elderly, possibly due to the limited data on chemotherapy efficacy
among patients age ≥ 70 years (Trimble et al, 1994). Co-morbidity
was absent in about 2/3 of the patients aged ≥ 70 who did not
receive chemotherapy. In this study, the information collected on
co-morbid conditions was done retrospectively and is probably not
complete. However, the results are compatible with those previ-
ously reported (Jouve et al, 1998; Mahoney et al, 2000), and
strongly suggest that the age factor per se is limiting chemotherapy
prescription. 
Recent data provided reassuring evidence on the tolerance, as
well as on the efficacy of chemotherapy among elderly patients
with colon carcinoma (Ross et al, 1998; Popescu et al, 1999).
Arbitrary age cut-off appears therefore unjustified. The current
study does not show any significant differences in chemotherapy
efficacy between age-groups (χ 2 interaction test between age and
chemotherapy = 5.6, P = 0.13). In particular, among the 9 patients
age ≥ 70 years who received chemotherapy, all except 1 were alive
after 5 years. Because cancer occurs more often in the elderly (in
this study, one fourth of stage III colon cancer concerned patients
age ≥ 70 years), the indication for chemotherapy among this group
is a public health matter that should not be neglected. The adjuvant
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Table 3 Distribution of stage III colon carcinoma patients and estimation of the effect of tumour characteristics on adjuvant chemotherapy
use 
Adjuvant chemotherapy Crude effect Adjusted effect 
Yes No ORa (95%CI) ORb (95%CI) 
(cases) (controls)
n = 55 n = 127
Anatomical site 
Transverse colon 10 31 1c 1c
Descending colon 4 7 0.93 (0.16–5.14) 0.53 (0.08–3.42) 
Sigmoid colon 25 33 1.42 (0.53–3.79) 1.38 (0.44–3.31) 
Caecum 7 26 0.35 (0.09–1.27) 0.23* (0.05–0.99) 
Ascending colond 9 21 0.57 (0.17–1.98) 0.53 (0.13–2.11) 
Not specified 0 9 Excluded Excluded
Tumour differentiation 
Well 5 18 1c 1c
Moderately 31 87 2.05 (0.58–7.21) 2.37 (0.56–9.92) 
Poorly 17 14 10.26** (2.35–44.84) 12.55** (2.16–73.07) 
Unknown 2 8 Excluded Excluded
Size of tumour (cm) 
≤ 31 3 2 6 1 c 1c
≤ 4 14 41 0.65 (0.23–1.82) 0.46 (0.14–1.52) 
≤ 5 16 24 1.03 (0.35–3.02) 0.95 (0.27–3.34) 
≥ 6 10 34 0.43 (0.14–1.32) 0.60 (0.17–2.16) 
Unknown 2 2 Excluded Excluded
TNM classification 
T1 1 1
T2 7 6 1c 1c
T3 40 99 0.33 (0.10–1.14) 0.10** (0.02–0.42) 
T4 7 19 0.28 (0.06–1.28) 0.16* (0.03–0.86) 
Unknown 0 2 Excluded Excluded
TNM classification 
N1 33 92 1c 1c
N2 15 22 1.40 (0.57–3.40) 1.03 (0.36–2.91) 
N3 7 10 3.21 (0.93–11.05) 2.37 (0.59–9.50) 
Unknown 0 3 Excluded Excluded
aOdds ratio adjusted for age (continuous); bOdds ratio adjusted for age (continuous), period (continuous), cancer sub-site (caecum, other),
differentiation (well, other), lymph node classification (N1, N2, other), and tumour classification (T1 and T2, T3, other); cReference
category; dAppendix included; * P < 0.05, **P < 0.01, ***P < 0.001. 
] ]chemotherapy use was higher among patients with poorly differ-
entiated tumours, indicating a prescription targeting patients
presenting carcinogenic criteria associated with a worse prognosis.
However, there are no real indications against treating patients
with well or moderately differentiated tumours. With regard to
local invasion, there was a lesser propensity to treat tumours
invading through the muscularis propria when compared with
more favourable stages. This was also observed for caecal cancer,
which is often diagnosed at a more advanced stage, probably due
to its possibility to extend before occurrence of symptoms such as
occlusion (Cohen et al, 1997). The worse general condition and
the obstructive presentation (Wolmark et al, 1983) are likely
to explain the lesser probability of being treated when the local
invasion increases. There was a general tendency of reduced
chemotherapy use among widowed, foreigners and patients
belonging to lower socioeconomic class, demonstrating once more
that the disfavoured have a lower access to optimal treatment
(Polednak, 1989). These last results were not significant, probably
because of the low power of the study. Reassuringly, the propen-
sity of being treated was similar in private institutions and the
university hospital sector, even after an additional adjustment for
socioeconomic status (OR: 1.1; 95%CI: 0.5–2.7). 
Beyond clinical trials, we have hardly any information on the
effect of adjuvant chemotherapy in routine health care practice.
With regard to data available in current practice derived from the
US national cancer data base, patients with stage III carcinoma
diagnosed between 1985–1993 were found to have an increase of
3% of the 3-year relative survival (Jessup et al, 1996). That study,
however, involves prescriptions before 1990, a period when
various drugs were used without proven effectiveness. In other
studies, effectiveness of chemotherapy in stage III carcinoma was
not reported (Beart et al, 1995; Jouve et al, 1998). 
We observed a relative reduction in death rates of 65% among
treated patients (95% CI: 32–82%), i.e. approximately twice that
expected from clinical trials (Moertel et al, 1990; Wolmark et al,
1993; Francini et al, 1994; IMPACT, 1995; O’Connell et al, 1997;
Mamounas et al, 1999). This important difference in survival is not
generated from a randomised study, and partly reflects the lower
propensity to give chemotherapy to patients with putative poorer
prognosis. In current practice the choice, whether to treat or not, is
based on the presence of co-morbid conditions: the observed 5-
year survival in untreated patients was 34% compared to approxi-
mately 43% in control groups in clinical trials (Laurie et al, 1989;
Francini et al, 1994). The 5-year survival in treated patients (70%)
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Table 4 Effect of adjuvant chemotherapy and prognostic factors on instantaneous mortality rates after surgery for stage III colon
carcinoma 
Cox proportional hazards  Cox proportional hazards 
model accounting for  model accounting for other 
age only prognostic factors 
Cases Deaths Hazard ratioa (95% CI) Hazard ratiob (95%CI) 
n = 182 n = 95
Chemotherapy 
No 127 81 1c 1c
Yes 55 14 0.37** (0.20–0.68) 0.35** (0.18–0.68) 
Age-group (years) 
<6 0 4 5 1 8 1 c 1c
60–69 43 18 1.20 (0.62–2.30) 1.54 (0.78–3.02) 
≥ 70 94 59 2.13** (1.25–3.61) 1.68 (0.95–2.97) 
Period of diagnosis 
1990–1992 75 49 1c 1c
1993–1994 57 30 0.76 (0.48–1.20) 0.77 (0.47–1.26) 
1995–1996 50 16 0.49* (0.28–0.87) 0.51 (0.27–0.96) 
Anatomical site 
Transverse colon 41 20 1c 1c
Descending colon 11 4 0.87 (0.30–2.54) 0.68 (0.21–2.22) 
Sigmoid colon 58 28 1.48 (0.82–2.66) 1.55 (0.84–2.85) 
Caecum 33 20 1.72 (0.92–3.21) 1.52 (0.80–2.88) 
Ascending colon 30 18 1.90 (1.00–3.61) 1.70 (0.87–3.31) 
Not specified 9 5 Excluded Excluded 
TNM classification 
T1, T2 15 6 1c 1c
T3 139 71 1.36 (0.59–3.14) 0.98 (0.40–2.36) 
T4 26 18 2.12 (0.84–5.36) 1.43 (0.55–3.73) 
Unknown 2 – Excluded Excluded 
TNM classification 
N1 125 60 1c 1c
N2 37 23 2.32** (1.39–3.87) 2.51*** (1.50–4.21) 
N3 17 12 1.77 (0.95–3.30) 2.50** (1.29–4.86) 
Unknown 3 – Excluded Excluded 
aHazard ratio adjusted for age (continuous); bHazard ratio adjusted for age (continuous), chemotherapy (no, yes), period (continuous), 
site of the tumour (caecum, other), T classification (T1 and T2, T3, T4, unknown), N classification (N1, N2, N3, unknown); cReference
category; *P < 0.05, **P < 0.01, ***P < 0.001. is very close to that observed in the treated group in clinical trials
(approximately 70%) (Laurie et al, 1989; Francini et al, 1994). To
minimise the effect of patient selection we excluded all patients
who died within 6 months of diagnosis, and obtained a very similar
result of chemotherapy effectiveness. 
CONCLUSION 
Adjuvant chemotherapy has proved its effectiveness for stage III
colon carcinoma patients, however, it has not reached its full
potential in daily practice. The probability of being treated remains
low, particularly among the elderly. This non-randomised study
based on a relatively small group of patients confirms the benefi-
cial effect of adjuvant chemotherapy use in routine practice. 
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